If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Cyramza ® (ramucirumab) injection
10 mg/mL solution
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
CYRAMZA® (ramucirumab): Approval for Treatment of HCC
Cyramza (ramucirumab), as a single agent, is indicated for the treatment of HCC who have an AFP ≥400 ng/mL and have been treated with sorafenib.
On May 10, 2019, the FDA approved ramucirumab as a single agent for the treatment of patients with HCC who have an AFP ≥400 ng/mL and have been treated with sorafenib therapy.1
Enclosed Prescribing Information
CYRAMZA® (ramucirumab) injection, for intravenous use, Lilly
1. Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
Glossary
AFP = alpha-fetoprotein
FDA = Food and Drug Administration
HCC = hepatocellular carcinoma
Date of Last Review: March 28, 2019
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 8am - 7pm ET
